- Home
- ASTH vs PVLA Comparison
ASTH vs PVLA Comparison
Compare ASTH & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ASTH | PVLA |
|---|---|---|
| Founded | 1994 | 2015 |
| Country | United States | United States |
| Employees | N/A | 14 |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.6B |
| IPO Year | 2015 | N/A |
Fundamental Metrics
Financial Performance| Metric | ASTH | PVLA |
|---|---|---|
| Price | $33.52 | $122.94 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 15 |
| Target Price | $34.86 | ★ $171.87 |
| AVG Volume (30 Days) | ★ 397.3K | 205.7K |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.46 | N/A |
| Revenue | ★ $519,907,752.00 | N/A |
| Revenue This Year | $27.38 | N/A |
| Revenue Next Year | $10.78 | $104,350.18 |
| P/E Ratio | $71.34 | ★ N/A |
| Revenue Growth | ★ 45.90 | N/A |
| 52 Week Low | $18.08 | $20.20 |
| 52 Week High | $34.80 | $151.18 |
Technical Indicators
Market Signals| Indicator | ASTH | PVLA |
|---|---|---|
| Relative Strength Index (RSI) | 76.80 | 49.67 |
| Support Level | $28.59 | $108.99 |
| Resistance Level | $34.49 | $133.53 |
| Average True Range (ATR) | 1.38 | 6.87 |
| MACD | 0.43 | -0.41 |
| Stochastic Oscillator | 83.97 | 42.79 |
Price Performance
Historical ComparisonAbout ASTH Astrana Health Inc.
Astrana Health Inc is a patient-centered, physician-centric integrated population health management company. The company is working to provide coordinated, outcomes-based medical care cost-effectively. It is focused on physicians providing high-quality medical care, population health management, and care coordination for patients, particularly senior patients and patients with multiple chronic conditions. The company's three reportable segments are Care Partners, Care Delivery, and Care Enablement. It generates the majority of its revenue from the Care Partners segment.
About PVLA Palvella Therapeutics Inc.
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.